Phenylephrine

證據等級: L5

預測適應症: 3 個

Phenylephrine: From Topical Nasal Decongestant to Nasal Cavity Disease

One-Sentence Summary

Phenylephrine is a selective α1-adrenergic agonist whose established pharmacology is topical vasoconstriction of nasal/ocular mucosa, used clinically as a decongestant prior to nasal procedures. The TxGNN model predicts it may be effective for Nasal Cavity Disease, with 8 clinical trials and 8 publications currently supporting this direction, including one completed Phase 2 RCT and one placebo-controlled RCT in the literature.

Quick Overview

Item	Content
Original Indication	Not formally documented in license records (drug not currently marketed); established pharmacological use as a topical nasal/ocular decongestant and vasoconstrictor
Predicted New Indication	Nasal Cavity Disease
TxGNN Prediction Score	99.97% (rank 1230)
Evidence Level	L2
US Market Status	Not Marketed
Number of Licenses	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in DrugBank (data gap DG002). Based on known pharmacology, phenylephrine is a selective α1-adrenergic receptor agonist that acts on nasal mucosal vascular smooth muscle to produce vasoconstriction, reducing mucosal congestion and swelling. This local vasoconstrictive effect is already well established in clinical practice (e.g., decongestion prior to nasoendoscopy, bleeding control during endoscopic sinus surgery), so the “new” indication of nasal cavity disease is essentially a formalization of existing off-label/procedural use rather than a novel mechanistic hypothesis.

The relationship between this established use and the predicted indication is therefore mechanistically direct: both rely on the same α1-mediated vasoconstriction of nasal mucosa. The supporting evidence largely comes from ENT procedural settings (nasoendoscopy, functional endoscopic sinus surgery, dacryocystorhinostomy) where phenylephrine or phenylephrine-containing combinations (e.g., Co-phenylcaine, Polydexa with phenylephrine) are used for decongestion and improved visualization — reinforcing plausibility while also indicating that most current evidence targets procedural/symptomatic endpoints rather than disease-modifying treatment of nasal cavity disease as a diagnosis.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03380715	N/A	Completed	106	Co-phenylcaine (phenylephrine + lidocaine) nasal spray vs. nasal nebulization for decongestion/local anesthesia before rigid nasoendoscopy
NCT00562120	Phase 2	Completed	21	Double-blind, four-way crossover RCT using acoustic rhinometry to assess nasal congestion after allergen challenge
NCT03228914	Phase 4	Completed	20	Comparison of oxymetazoline vs. epinephrine (same α-agonist decongestant class) on blood loss and surgical field visualization before endoscopic sinus surgery
NCT06443255	Phase 3	Completed	16	Cocaine vs. lidocaine/xylometazoline vs. saline for intranasal analgesia before awake nasotracheal intubation
NCT06457100	Phase 1/2	Active, not recruiting	60	Esmolol vs. lidocaine IV infusion on recovery quality after functional endoscopic sinus surgery (shared procedural context, no direct phenylephrine arm)
NCT03962634	Phase 2	Terminated	3	Kovanaze (tetracaine + oxymetazoline) nasal mist vs. articaine for maxillary dental pulpal anesthesia
NCT04104789	Phase 2	Withdrawn	0	Repeat of Kovanaze vs. articaine maxillary anesthesia trial; withdrawn before enrollment
NCT02993770	N/A	Unknown	120	Endonasal-endoscopic vs. external dacryocystorhinostomy for nasolacrimal duct obstruction

Note: Most trials involve phenylephrine-containing combination products or same-class α-agonists used for procedural decongestion, not disease-specific therapeutic endpoints for nasal cavity disease per se.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15854186	2005	RCT	Int J Clin Pract	Double-blind placebo-controlled RCT (n=98): Cophenylcaine spray reduced pain/discomfort during flexible nasendoscopy vs. placebo
25133491	2014	RCT/Cohort	PLoS One	Triple-blind RCT on topical tranexamic acid effect on bleeding and surgical field quality during FESS in chronic rhinosinusitis
9780066	1998	Cohort	Int J Pediatr Otorhinolaryngol	Acoustic rhinometric evaluation of nasal cavity/nasopharynx geometry after adenotonsillectomy
40899890	2025	Experimental/Clinical safety-efficacy	Vestnik Otorinolaringologii	Safety and efficacy evaluation of Polydexa nasal spray with phenylephrine in acute rhinosinusitis
37184554	2023	Review	Vestnik Otorinolaringologii	Differential diagnosis of chronic nasal disease after surgery, referencing Polydexa spray with phenylephrine
37970776	2023	Review	Vestnik Otorinolaringologii	Pathogenetic approach to treatment of inflammatory diseases of the nose and paranasal sinuses
7378007	1980	Case report	Arch Ophthalmol	Cocaine toxicity during dacryocystorhinostomy, with one patient also reacting to intranasal phenylephrine
1375136	1992	In vitro study	Clin Otolaryngol Allied Sci	Preliminary in vitro study of drug effects (including nasal decongestants) on ciliary beat frequency

US Market Information

Phenylephrine currently has no marketed license records in this dataset (Market Status: Not Marketed, 0 licenses on file).

Safety Considerations

Please refer to the package insert for safety information. No key warnings, contraindications, or drug interaction data are currently available in this evidence pack (data gap DG001, flagged as Blocking for safety pre-assessment).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic link is strong (established α1-agonist vasoconstrictor pharmacology already used in nasal procedures) and is supported by one completed Phase 2 RCT and one placebo-controlled RCT (L2 evidence), but a Blocking data gap in TFDA/FDA label warnings and contraindications (DG001) prevents a full safety pre-assessment (S1), and most current evidence targets procedural/symptomatic endpoints rather than a distinct “nasal cavity disease” treatment claim.

To proceed, the following is needed:

Official package insert / label warnings and contraindications (DG001, Blocking)
Confirmed mechanism of action documentation from DrugBank (DG002)
Clarification of original approved indication(s) and any prior license history
Route compatibility assessment (currently marked pending in evidence pack)
Further review distinguishing procedural decongestant use from a genuine disease-modifying indication for nasal cavity disease

Other candidate indications screened for this drug (acute laryngopharyngitis, trigeminal autonomic cephalalgia) were both placed on Hold — the former lacks any supporting trials or literature (L5, model-prediction only), and the latter’s literature base consists exclusively of diagnostic pupillometry studies using phenylephrine as a testing reagent, not as a therapeutic agent (L4).

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.